Pharma Blog Watch

Generics Threaten J&J (PharmaGossip)
In this post, the pharma insider discusses recent approvals of generic versions of Johnson & Johnson (J&J) products, including one for Teva’s version of Risperdal. However, “[t]he most pressing threat to [J&J’s] business came from Mylan Laboratories, which last month won U.S. approval to sell generic versions of three Topamax doses with combined annual sales of approximately $1.4 billion.”

The drugmaker has responded by attempting to block the launch of Mylan’s product. “As the first to file for approval of generic Topamax, Mylan has six months’ exclusivity in the marketplace so could reap a rich harvest before other generics enter the field.”